TTK Healthcare Ltd:-Buy/sell/growth prospects and recommendation,news and results,target and analysis,view and outlook,multibagger

Scripscan:TTK Healthcare Ltd
cmp:400
Code:507747

Story:TTK Healthcare Limited engages in pharmaceutical, consumer products, and medical devices businesses. Its Pharmaceuticals division deals in herbal and allopathic formulations in various therapeutic areas. The company offers female healthcare, pain management, neurotrophic, gastrointestinal, male and female fertility, nutritional, cardiac care, derma, respiratory care, and urinary specialty products, as well as calcium supplements, delivery care injections, and haematinics. This division also provides veterinary products, including anthelmintics, anti infectives, antihistaminics, anti-inflammatory, oral calcium supplements, ectoparasiticides, fertility promoters, herbal liver tonics, vitamins, digestive tonics, herbal galactogogue, mineral mixture products, enzymes, toxin binders, and immunomodulators for veterinarians, hatcheries, poultry farms, dairy farms, and animal feed manufacturers. The company’s Consumer Products division involves in the distribution of products marketed under its own brands, including Woodward’s Gripe Water and baby bath soaps; EVA deodorants, talc, and lip care products; Good Home air fresheners and scrubbers; Durex and Kohinoor brand of condoms; and the Scholl range of foot care products. Its Medical Devices division manufactures and distributes bio-prosthetic valves, heart valves, vascular grafts, coronary stents, and stents for aneurysm repair; and orthopedic implants, including total knee replacement systems. The company also produces maps and map-based publications; and manufactures potato and cereal based pellets.TTK Healthcare appears to be one of the most interesting rerating candidate with brands like Eva and Woodward's among other things in the package.Under the “EVA” brand the company has launched skin care, moisturizer, perfumes etc. The competition is quite strong in these segments but the overall growth has been satisfactory.With market cap of 300 Crs it doesn't appear too expensive, considering that they have done very well in the last two years and once might expect them to continue the performance as there doesn't seem to be any cyclical nature in its business.This company is also debt free and well established company with a top line of over Rs 400 crore and expected EPS of 20.The company is interesting as its present market cap of Rs 300 cr does not capture the possible “sum of the part” valuations of all its divisions. The company is available at dirt cheap price and a possible value unlocking can increase the shareholder value immensely.One can buy it with an expected CAGR return of 25% for the next 5 years.